Pharmacokinetics.

Slides:



Advertisements
Similar presentations
Assignment 6 Metabolism
Advertisements

Nonlinear pharmacokinetics
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Pharmacology Department
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
CLEARANCE (CL) describes the efficiency of irreversible elimination of a drug from the body by excretion of unchanged drug. Metabolic conversion of the.
Quantitative Pharmacokinetics
Nonlinear Pharmacokinetics
Pharmacokinetics Introduction
Anticonvulsant Pharmacokinetics Dennis Mungall, Pharm.D. Director, Virtual Education, NTPD Associate Professor Pharmacy Practice Ohio State University.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
Alison Wong Meme Phung Zhi Yuan Quek. CASE Mr. AR, aged 55 years Recently been prescribed amiodarone as treatment for atrial tachyarrhythmia Medications.
MECHANISTIC PHARMACOKINETICS: COMPARTMENTAL MODELS
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
Quantitative Pharmacokinetics
Plasma Protein Binding
PHARMACOKINETICS Definition: quantitative study of drug absorption, distribution, metabolism, and excretion (ADME), and their mathematical relationship.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
Pharmacology Department
Clinical Pharmacokinetics of PHENYTOIN & OTHER ANTIEPILEPTICS
Lecture 2 Clearance, maintenance dose and AUC
Do We Need to Optimize Protein Binding in Drug Discovery? NEDMDG Summary Meeting Xingrong Liu, Ph.D. Genentech.
Pharmacokinetics 2 General Pharmacology M212
Foundation Knowledge and Skills
Pharmacokinetics: Digoxin Allie Punke
Pharmacokinetics: Warfarin
By : Dr. Roshini Murugupillai
Pharmacokinetics 3rd Lecture
Allie punke Pharmacokinetics tutoring Fall 2016
Anticonvulsants: Phenytoin
Pharmacokinetics.
Allie punke Pharmacokinetics tutoring Fall 2016
Allie punke pharmcokinetics Allie punke
Factors Affecting Drug Activity
Pharmacokinetics Tutoring
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics.
PHARMACOKINETICS Allie punke
Pharmacokinetics Tutoring
Pharmacokinetics: Warfarin
Dosing Regimen Concepts: 2-C, MM, Individualization principles
Pharmacokinetics.
Anticonvulsants: Valproic acid
Understanding the Basics of Pharmacology
Pharmacokinetics.
Pharmacokinetics.
Pharmacokinetics: Theophylline
Pharmacokinetics: immunosuppressive drugs
PHARMACOKINETICS Allie punke
Pharmcokinetics Allie punke.
Clinical Pharmacokinetics
Pharmcokinetics Allie punke.
Pharmacokinetics.
Therapeutic Drug Monitoring
Hawler Medical University
Selected Bioavailability and Pharmacokinetic Calculations
Principle of Basic Clinical Pharmacokinetic parameters
Therapeutic Drug Monitoring chapter 1 part 1
Clinical Pharmacokinetics
Q1: Drug A is a small and hydrophilic compound that distributes to extracellular fluids only. It has a volume of distribution of 5.6 L in a healthy 70-kg.
Therapeutic Drug Monitoring
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Presentation transcript:

Pharmacokinetics

Protein binding

Protein binding A certain drug is 80% protein bound. Another drug is given that decreases the protein binding to 60%. Which of the following would change? A. Loading dose B. Maintenance dose C. Half life D. AUC, unbound E. None of the above E

Protein binding Which of the following do NOT affect the half life of a drug? A. fut B. fup C. CLu D. Vt Which of the following MUST change for you to change the LD? A. CLu C. fut Which of the following MUST change for you to change the MD?* B C A

Protein binding What type of drugs does albumin bind? A. Acidic B. Basic What type of drugs does AAG1 bind? Which type of protein has high capacity, but low affinity? A. Transcortin B. Albumin C. Thyroid binding globulin D. A and C Which type of protein has low capacity, but high affinity? A B D

Protein binding A drug is 75% protein bound with a therapeutic range of 10 to 20 mg/L. Calculate the unbound, therapeutic range of the drug. When are can you simplify this formula? A. When the drug is bound to a high capacity, low affinity protein such as albumin B. When the drug is bound to a low capacity, high affinity protein such as transcortin C. When 1/Ka>>Cu D. When 1/Ka<<Cu E. A and C 2.5 to 5 E

Protein binding When you do simplify the formula, what are you saying? A. fu is only affected by N and Ka B. Cu affects fu C. fu and Cu are independent D. A and C If you have a protein that tends to become saturated with a drug, what does this mean? D B

Protein binding For a drug that primarily binds albumin, what happens to fup if you increase Ka? A. Increase fu B. Decrease fu C. Nothing, they are independent For a drug that primarily binds albumin, what happens to fup if you decrease Cu? B C

Protein binding Prednisone binds transcortin and albumin, while methylprednisolone only binds to albumin. How does the fu for each drug change with increasing plasma concentration? A. Fu, prednisone is the SAME, fu, methylpred INCREASES B. fu, prednisone INCREASES, fu, methylpred is the SAME C. fu, pred INCREASES, fu, methylpred DECREASES D. fu, pred is the SAME, fu, methylpred is the SAME Based on the answer, what happens to: CL CL,u Vss Vss,u t1/2 B 6.1 recitation

Protein binding A drug is able to displace two drugs: Drug A (fup=0.001) and Drug B (fup=0.5). Which drug interaction has the biggest therapeutic impact? A. Drug A B. Drug B If fut >> fup, what does this mean? A. Volume of distribution is very low B. Volume of distribution is very high C. Neither, unable to tell from this information A

Protein binding What should you look at to determine the volume of distribution? A. fup B. fut C. Neither D. Ratio of fup and fut D

Protein binding In the aspirin phenytoin example, aspirin increased the fup of phenytoin. Why was the LD not changed? In the aspirin phenytoin example, aspirin increase the fup of phenytoin. Why was the MD not changed? If fu increases, what happens to Clu? CL? What is CLu a measure of? Vss,u was not affected CL,u was not affected Nothing happens to CLu—they are independent. If increase fu, increase CL Clu is a measure of innate metabolic activity.

Protein binding A CKD receiving phenytoin (Css=8mg/L in) has an albumin level of 2g/dl. Determine how to manage the patient. Normal levels are Css= 10-20mg/L, Css,u=1-2mg/L. A. Increase dose, since 8mg/L is below Css B. Decrease dose C. Leave dose the same C, within Css, u

Protein binding If Drug A is given with Drug B which causes a displacement of A from tissue binding sites only, therefore doubling fraction unbound in tissues. Determine what happens to the following parameters: t1/2 AUC,u AUC Vss,u Vss CL,u CL 5.2 from recitation

Protein binding When valoproic acid is given with phenytoin, phenytoin’s plasma protein binding decreases from 90% to 84%. Also, valproic acid decreases the unbound CL of phenytoin, and displaces phenytoin from tissue binding sites; no change in half-life. What happens to… AUC? AUC,u? LD? MD? 9 recitation

Hepatic cleraance

Hepatic clearance If a patient is on 600mg BID IV of Linezolid. The medical team wants to switch the patient to oral therapy. What dose should you recommend? Fe=1 600 mg BID

Hepatic clearance Calculate F* for a drug that has a ER of 0.3. Calculate F for a drug with the following characteristics: fa=0.2, fg=0.1, ER=0.3 A drug with an F* of 0.1 is classified as high or low extraction? Enzyme induction or inhibition occur almost immediately? For a drug with a ER=0.2, what is CL dependent on? A. Q B. fu C. CL,int D. B and C For a drug with a ER=0.99, what is CL dependent on? 0.7 0.014 HIGH Inhibition D A